UNSPSC 51332875: Thioproperazine dimesilate

This classification denotes an antipsychotic agent with the molecular formula C22H30N4O2S2.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71P630M192, chemically known as n,n-dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine-2-sulfonamide, dimethanesulfonate, but more generally known as thioproperazine dimesilate, which bears US NIH Compound Identifier 92178.

European Medicines Agency schedules thioproperazine dimesilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10983MIG. Most nations, for tariff purposes, schedule thioproperazine dimesilate under HS 29350090. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O.

UNSPSC 51332875 Thioproperazine dimesilate is a Commodity code that nominally names a specific antipsychotic pharmaceutical, but recent state and local opportunities posted under this code do not reflect procurement of thioproperazine itself. Instead, issuing bodies are using the code to solicit naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The actual scope of work reflects pharmaceutical supply and pharmacy benefit management rather than a single active pharmaceutical ingredient. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The mix suggests that code assignment may reflect administrative convenience or legacy categorization rather than precise commodity matching, making this code a weak signal for targeted business development.

Recent activity spans Florida, Texas, and Minnesota through a mix of procurement types: Seminole County released an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (note: the due date predates the posting date, indicating a data quality issue in the source); the Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment capabilities; and the Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) in January 2026 for generic pharmaceuticals and OTC products across multiple states, with proposals due March 26, 2026. The lack of activity directly matching thioproperazine dimesilate, combined with the wide variance in actual commodities being solicited under the code, suggests limited relevance for vendors focused on that specific pharmaceutical product.